



Ind-Swift LABORATORIES LIMITED


(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
 Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
 E-mail : info@indswiflabs.com Website : www.indswiflabs.com
 CIN No. L24232CH1995PLC015553



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th, June , 2018

Particulars	Quarter Ended 30.06.2018	Quarter Ended 31.03.2018	Quarter Ended 30.06.2017	Year Ended 31.03.2018
	UnAudited	Audited	UnAudited	Audited
Income from Operations:				
Revenue from operations	17876.03	21650.45	16408.99	73129.33
Other Income	400.93	537.09	436.40	1837.87
Total Revenue	18276.96	22187.54	16845.39	74967.20
EXPENSES:				
a Cost of Materials Consumed	11088.21	9168.97	9675.41	35201.28
b.Purchase of stock in Trade	33.35	0.00	0.00	34.34
c.(Increase)/decrease in FG,WIP & stock in trade	(2369.82)	(264.68)	303.40	2270.50
d. Employee benefit	2349.32	3044.53	1845.53	8930.58
e.Finance Costs	480.01	(2849.35)	2088.82	2831.38
f. Depreciation	2527.38	2144.40	2206.40	8661.61
g. Other expenditure	3805.50	4927.36	3019.91	14049.78
TOTAL EXPENSES	17913.95	16171.23	19139.47	71979.46
Profit(loss) before exceptional and Tax	363.01	6016.31	(2294.08)	2987.74
Exceptional Items	(2387.76)	129.59	0.00	129.59
Profit(loss) before Tax	2750.77	5886.72	(2294.08)	2858.15
Tax Expenses :-				
(1)Current Tax	0.00	0.00	0.00	0.00
(2)Deferred Tax	0.00	1095.70	0.00	1095.70
Profit (+)/ Loss (-) for the period from continuing	2750.77	4791.03	(2294.08)	1762.45
Profit (+)/ Loss (-) from discontinuing operations	0.00	0.00	0.00	0.00
Tax Expense of discounting operations	0.00	0.00	0.00	0.00
Profit (+)/ Loss (-) from discontinuing operations(after	0.00	0.00	0.00	0.00
Net Profit/(Loss) for the period	2750.77	4791.03	(2294.08)	1762.45
Other Comprehensive Income				
A) Items that will not be reclassified to P/L A/c	0.00	0.00	0.00	0.00
B) items that will be reclassified into P/L A/c	0.00	126.32	0.00	126.32
Other Comprehensive Income / Loss for the period , net of	0.00	126.32	0.00	126.32
Tax				
Total Comprehensive Income for the Period	2750.77	4664.71	(2294.08)	1636.14
Paid up Equity Share Capital(Face Value of Rs. 10/- per Share)	4527.73	4527.73	4473.96	4527.73
Reserve excluding revaluation reserves				
EPS (of Rs. 10/- each) (Not annualised)				
Basic	6.08	10.63	(5.13)	3.91
Diluted	6.08	10.63	(5.13)	3.91





Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com
CIN No. L24232CH1995PLC015553




Notes:

1. For the loans assigned to the Edelweiss Asset Reconstruction Company Limited (EARCL) in 2017-18, the company has executed Master Restructuring Agreement with EARCL on behalf of the EARCL trusts whereby the existing debt stands restructured.
2. During the Quarter, Company raised Funds of Rs. 424.50 crores through private placement of 10% Secured Listed Rated Redeemable, Non-Convertible Debentures, funds raised were utilised mainly for the settlement of the debts due to the State Bank of India the consortium leader. The Company is in process of execution of security document for creation of 100% asset cover for the 10% Secured Listed Redeemable Non-Convertible Debentures issued by the Company.
3. The settlement with balance lenders has also been agreed upon and will be completed in the upcoming quarter.
4. Consequent to the full absorption of above settlements a sum of Rs. 83.73 crores has been recognised as Exceptional Income during the quarter in accordance with Ind-As 32 and IND-AS 109. The Company has also written off during the quarter Debit balances amounting to Rs. 59.86 crores as an exceptional expense. The net result of such exceptional items is reflected as exceptional income of Rs. 23.87 crores in this quarter results.
5. Revenue from operations and expenses for the quarter ended 30th June 2017 and year ended 31st March 2018 being inclusive of excise duty is not comparable with the corresponding figures for the quarter ended 31st March 2018 and 30th June 2018 being exclusive of goods and service tax ("GST") which subsumed excise duty. The following additional information has been provided in respect of revenue from operations for comparison purposes:-

Particulars	(Rs. In Lacs)		
	Quarter Ended 30.06.2018	Quarter Ended 31.03.2018	Quarter Ended 30.06.2017
Revenue from operations(A)	17876.03	21650.45	16408.99
Excise duty on sale of goods(B)		296.42	296.42
Revenue from operations excluding excise duty on sale of goods (A-B)	17876.03	21354.04	16112.58

6. No adjustment has been made in respect of Deferred Taxes as per Ind-AS 12, as the same would be provided at year end.
7. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 14th Aug, 2018.
8. The previous period figures have been re-grouped and re-arranged wherever necessary.
9. The Company is exclusively in the Pharmaceutical Business segment.

Place: Chandigarh
Date: 14.08.2018



For Ind-Swift Laboratories Limited

N.R. Munjal

N.R. Munjal

Vice Chairman cum Managing Director